

Contributors to this Issue

Andersson H.	1857	Kondratenko M. A.	1829
Blechert S.	1873	Kunz U.	1833
Bolm C.	1795	Lamouille T.	1841
Bräse S.	1845	Lauterwasser F.	1845
Bräse S.	1849	Lauterwasser F.	1849
Buchmeiser M. R.	1837	Leadbeater N. E.	1845
Burguete M. I.	1821	Leadbeater N. E.	1849
Chan A. S. C.	1867	Lemaire M.	1841
Chinchilla R.	1817	Ley S. V.	1813
Claßen A.	1795	Luis S. V.	1821
Cole D. C.	1791	Maillard B.	1877
Connon S. J.	1873	Malkoch M.	1857
Dahmen S.	1845	Malmström E.	1857
Dahmen S.	1849	Matsuo T.	1825
Deleuze H.	1877	Mayoral J. A.	1821
Díez-Barra E.	1821	Moberg C.	1857
Ditto L.	1799	Mondain-Monval O.	1877
Dodsworth D. J.	1817	Muñiz K.	1795
Fan Q.-H.	1867	Nájera C.	1817
Fraile J. M.	1821	Nicewonger R. B.	1799
García J. I.	1821	Nisar M.	1803
García-Verdugo E.	1821	Nozaki K.	1825
González R.	1821	Parang K.	1863
Hallman K.	1857	Rigby J. H.	1829
Hérault D.	1841	Rogovoy B. V.	1809
Hermanns N.	1795	Saluzzo C.	1841
Herrerías C. I.	1821	Sharp E. L.	1845
Hirao A.	1853	Sharp E. L.	1849
Hiyama T.	1825	Shibahara F.	1825
Hodge P.	1803	Solodenko W.	1833
Hult A.	1857	Soriano J. M.	1817
Itsuno S.	1853	Stemme G.	1857
Jas G.	1833	Stock J. R.	1791
Jönsson C.	1857	Tanaka S.	1853
Kappel J. A.	1791	Taylor S. J.	1813
Katritzky A. R.	1809	Thomas A. W.	1881
Kell R. J.	1803	Varady L.	1799
Kerr D.	1799	Vvedensky V.	1809
Kirichenko N.	1809	Wang R.	1867
Kirschning A.	1833	Watson D.	1803

Cover Photograph, *Bioorganic & Medicinal Chemistry Letters*

2002: Representation of the inhibitor celecoxib in the active site of the COX-2 enzyme. The model has been derived from the 1cx2 crystal structure via docking and force-field calculations [Price, M. L. P.; Jorgensen, W. L. *J. Am. Chem. Soc.* **2000**, *122*, 9455–9466]. Monte Carlo simulations have then been used to develop a computational model to reproduce the observed activities of 45 celecoxib analogues [Wesolowski, S. S.; Jorgensen, W. L. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 267]. In the illustration, the shading reflects the distance between atoms of the inhibitor and the protein: the more red, the shorter the distance. The deep red region near the sulfonamide group includes residues H/R 513 and I/V 523, which provide the primary differences between the COX-1 and COX-2 binding sites. The figure was prepared using the Sybyl program by Dr. Erin M. Duffy.